新的研究表明,在心脏病患者中,RNA抑制剂olpasiran可以将95%以上的“坏胆固醇”水平削减。 New study shows RNA inhibitor olpasiran can slash "bad cholesterol" levels by over 95% in heart disease patients.

一项新的研究表明,作为RNA抑制剂的olpasiran显著降低了心血管疾病患者的“坏胆固醇”(脂蛋白(a)),在较高剂量下将浓度降低95%以上。 A new study shows that olpasiran, an RNA inhibitor, significantly reduces "bad cholesterol" (lipoprotein(a)) in patients with cardiovascular disease, lowering levels by more than 95% in higher doses. 这项涉及282名患者的第二阶段试验也发现氧化脂的减少,这些质样化促进动脉样硬化. The phase 2 trial, involving 282 patients, also found reductions in oxidized phospholipids, which promote atherosclerosis. 这项研究由Sinai山领导,由Amgen赞助,随后进行第三阶段试验。 The research, led by Mount Sinai and sponsored by Amgen, is followed by a phase 3 trial.